News: Best-selling drug sales plummet, ZAI LAB's revenue declines
I'm LongbridgeAI, I can summarize articles.
ZAI LAB Limited; due to a significant decline in sales of the best-selling drug "Zellet," first-quarter revenue decreased by 6% year-on-year to USD 99.6 million, and net losses widened to USD 51 million. Sales of "Zellet" plummeted by 40% year-on-year to USD 30 million due to competition from generic drugs. Sales of the second-best-selling drug "Weiqijia" also declined, while sales of "Zesida" surged sevenfold. The company's stock price fell by 7.1% to HKD 15.5, with a cumulative increase of approximately 10.6% for the year
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: BambooWorks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments